APRI (Aprinoia Therapeutics) Liabilities-to-Assets : 21.32 (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aprinoia Therapeutics Liabilities-to-Assets?

Aprinoia Therapeutics APRI Liabilities-to-Assets is 21.32 as of Dec. 2023.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Aprinoia Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was $105.44 Mil. Aprinoia Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $4.95 Mil. Therefore, Aprinoia Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 21.32.

Aprinoia Therapeutics  (NAS:APRI) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Aprinoia Therapeutics Liabilities-to-Assets Related Terms

Aprinoia Therapeutics Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Liabilities-to-Assets Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Liabilities-to-Assets
4.81 14.37 21.32

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Liabilities-to-Assets 4.81 0.00 14.37 6.66 21.32

APRI vs : Liabilities-to-Assets Comparison

For the Biotechnology subindustry, Aprinoia Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics Liabilities-to-Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Liabilities-to-Assets falls into.


Aprinoia Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Aprinoia Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=105.435/4.946
=21.32

Aprinoia Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=105.435/4.946
=21.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 21.32 mean?
Aprinoia Therapeutics (APRI) has a Liabilities-to-Assets of 21.32 as of Dec. 2023. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Liabilities-to-Assets too high?
Aprinoia Therapeutics' current Liabilities-to-Assets is 21.32.
How does Aprinoia Therapeutics' Liabilities-to-Assets compare to ?
Aprinoia Therapeutics' Liabilities-to-Assets of 21.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Liabilities-to-Assets is 21.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Liabilities-to-Assets of 21.32. The current Liabilities-to-Assets is 21.32. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Liabilities-to-Assets is 21.32 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.